EVQLV and Libera Bio are collaborating to develop and deliver new antibodies for intracellular cancer targets
EVQLV Inc. and Libera Bio SL have signed a collaboration agreement to jointly address intracellular targets, some of the most elusive cancer targets that represent unmet medical needs. Antibodies can be designed to engage very specific targets along cancer pathways A lots of the best validated intracellular targets for cancer are considered “untreatable” because large …